ProGnosis Biotech is a European Union (EU)-based manufacturer of innovative immunoassays for detecting and quantifying mycotoxins, allergens, genetically modified organisms (GMOs), antibiotic residues, adulterations, adenosine triphosphate (ATP), and viruses. The company, in addition to next-generation immunoassays, also develops its own antibodies internally, as well as reading hardware and software solutions. Through research and development (R&D), it creates accurate and reliable enzyme-linked immunosorbent assay (ELISA) and lateral flow tests, exporting its products to a network of over 70 countries. ProGnosis Biotech recently opened a subsidiary in the United Kingdom (UK) to serve the UK and Irish markets.